JJ_Photo_Skyline of J&J building_JJ_1Star.JPG

Newsroom

The latest news, information, and stories from Johnson & Johnson Innovative Medicine EMEA.

Press releases

The content in this section is intended for journalists.

Sorry, I don't understand. Please try again

98 Results

Filters

98 Results

Selected

Clear All

Oncology

CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) demonstrated significantly higher rates of minimal residual disease negativity compared to standard therapies in the CARTITUDE-4 study

89 percent of patients evaluable for minimal residual disease (MRD) assessment were MRD negative, with the majority reaching MRD negativity in less than 2 months¹

Results add to the overall survival (OS) benefits recently presented, as the first cell therapy to significantly extend OS versus standard therapies in multiple myeloma^1,2

December 10, 2024

Read more
Oncology

DARZALEX® (daratumumab) SC-based regimens improve MRD negativity and progression-free survival in newly diagnosed multiple myeloma, and overall survival in AL amyloidosis

New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with daratumumab SC were progression free at 4.5 years¹

AURIGA study shows higher rates of MRD negative conversion in subgroup patient populations disproportionately impacted by multiple myeloma²

Final analysis of Phase 3 ANDROMEDA study shows the addition of daratumumab to VCd significantly improves overall survival for patients with newly diagnosed AL amyloidosis³

December 9, 2024

Read more
Oncology

TECVAYLI®▼ (teclistamab) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma

100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy^1,2

December 8, 2024

Read more
Oncology

DARZALEX® (daratumumab) subcutaneous formulation shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smouldering multiple myeloma

First subcutaneous anti-CD38 therapy to demonstrate potential to prevent end-organ damage, and extend progression-free survival and overall survival based on findings from Phase 3 AQUILA study¹

December 8, 2024

Read more
Oncology

CHMP recommends RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer

The amivantamab plus lazertinib combination regimen offers potential to provide new standard of care as first-line option for adult patients with advanced NSCLC with EGFR ex19del or L858R substitution mutations¹

In the Phase 3 MARIPOSA study, amivantamab plus lazertinib significantly reduced risk of disease progression or death by 30 percent versus osimertinib monotherapy¹

November 15, 2024

Read more
Immunology

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren’s disease study

Adults with moderately-to-severely active Sjögren’s disease who received investigational FcRn blocker, nipocalimab, had improvements in disease activity scores at 24 weeks with accompanying significant reductions in IgG and autoantibody levels

Nipocalimab was granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren’s disease based on results from the Phase 2 DAHLIAS study

November 14, 2024

Read more
Oncology

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO®/DARZALEX® (daratumumab) as subcutaneous monotherapy for high-risk smouldering multiple myeloma

If approved, daratumumab will become the first treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering a novel approach to treat before the onset of active disease and the occurrence of end organ damage¹

November 8, 2024

Read more
Immunology

TREMFYA® (guselkumab) is the first IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn’s disease

A greater number of patients treated with subcutaneous TREMFYA® induction and maintenance achieved clinical and endoscopic remission at 48 weeks in the Phase 3 GRAVITI study versus placebo¹

TREMFYA® could become the first IL-23 treatment to offer both a subcutaneous and intravenous induction regimen for patients living with Crohn’s disease¹

October 29, 2024

Read more

CP-459038
September 2024

You are now leaving J&J Innovative Medicine EMEA

You are now leaving J&J Innovative Medicine EMEA

You are now leaving J&J Innovative Medicine EMEA

You are now leaving J&J Innovative Medicine EMEA

You are now leaving J&J Innovative Medicine EMEA

You are now leaving J&J Innovative Medicine EMEA

Press releases

You are now leaving J&J Innovative Medicine EMEA

You are now leaving J&J Innovative Medicine EMEA

You are now leaving J&J Innovative Medicine EMEA

You are now leaving J&J Innovative Medicine EMEA

You are now leaving J&J Innovative Medicine EMEA

You are now leaving J&J Innovative Medicine EMEA

Search Results

No Results

Recently Viewed

Press releases